Methods for identification of compounds stimulating insulin secretion
CA 2380983 A1 · Owner: Karolinska Innovations Ab · Inventors: Berggren, Per-Olof; Bertorello, Alejandro; Lundback, Thomas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
According to the invention .beta.-tubulin as well as a 65 kDa polypeptide , present in pancreatic .beta.-cells have been identified as molecular targets for sulfonylurea compounds. These findings enable for the identification of new insulin secretagogues. The invention thus relates to the use of sulfonylurea compounds, such as e.g. glibenclamide in methods for , identification of compounds binding the 65 kDa polypeptide or tubulin or , stimulating tubulin polymerization and/or turnover said compounds thereby , stimulating insulin secretion.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 10, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 10, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 10, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.